HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $650,709 | +3.5% | 7,264 | -1.6% | 0.01% | +12.5% |
| Q2 2023 | $628,418 | -3.2% | 7,381 | -6.0% | 0.01% | -11.1% |
| Q1 2023 | $649,505 | +4.8% | 7,849 | -0.4% | 0.01% | -10.0% |
| Q4 2022 | $619,998 | +5.3% | 7,883 | -1.0% | 0.01% | -9.1% |
| Q3 2022 | $589,000 | +13.7% | 7,959 | +0.1% | 0.01% | +10.0% |
| Q2 2022 | $518,000 | +10.2% | 7,949 | +6.9% | 0.01% | +25.0% |
| Q1 2022 | $470,000 | +18.1% | 7,436 | -0.9% | 0.01% | +33.3% |
| Q4 2021 | $398,000 | -25.6% | 7,504 | -1.1% | 0.01% | -40.0% |
| Q3 2021 | $535,000 | +0.4% | 7,586 | -5.2% | 0.01% | 0.0% |
| Q2 2021 | $533,000 | -53.5% | 8,002 | -22.5% | 0.01% | -58.3% |
| Q1 2021 | $1,146,000 | -4.6% | 10,319 | +2.0% | 0.02% | -7.7% |
| Q4 2020 | $1,201,000 | +36.0% | 10,115 | -0.1% | 0.03% | +18.2% |
| Q3 2020 | $883,000 | +5.5% | 10,121 | +8.3% | 0.02% | 0.0% |
| Q2 2020 | $837,000 | – | 9,342 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nitorum Capital, L.P. | 413,122 | $16,608,000 | 4.78% |
| Altalis Capital Management LLC | 88,055 | $3,540,000 | 3.97% |
| RUTABAGA CAPITAL MANAGEMENT LLC/MA | 513,619 | $20,647,000 | 3.54% |
| Black Creek Investment Management Inc. | 1,118,613 | $44,968,000 | 3.46% |
| HealthCor Management, L.P. | 1,150,000 | $46,230,000 | 2.61% |
| Van Berkom & Associates Inc. | 1,136,971 | $45,706,000 | 1.83% |
| AMERICAN CAPITAL MANAGEMENT INC | 567,896 | $22,829,000 | 1.77% |
| FULLER & THALER ASSET MANAGEMENT, INC. | 2,062,539 | $82,914,000 | 1.25% |
| Legato Capital Management LLC | 1,336 | $53,707,000 | 0.97% |
| HEARTLAND ADVISORS INC | 351,314 | $14,123,000 | 0.78% |